Table 3 Risk of colon cancer associated with different categories of HRT formulation or administration.
From: Colon cancer risk and different HRT formulations: a case-control study
e-case/e-ctrl | Adj. OR (95% CI) | |
|---|---|---|
Route of administration | ||
ORAL | ||
Ever | 99/381 | 0.76 (0.54–1.08) |
1–4 years | 17/108 | 0.54 (0.30–1.00) |
5–9 years | 27/125 | 0.61 (0.36–1.04) |
10+ years | 38/103 | 1.14 (0.68–1.92) |
TRANSDERMAL | ||
Ever | 24/99 | 1.17 (0.63–2.16) |
1–4 years | 6/29 | 0.98 (0.34–2.86) |
5–9 years | 5/32 | 0.87 (0.30–2.51) |
10+ years | 10/27 | 2.16 (0.73–6.36) |
OTHER | ||
Ever | 11/48 | 0.96 (0.40–2.31) |
1–4 years | 1/11 | n.d. |
5–9 years | 2/11 | n.d. |
10+ years | 5/19 | 1.15 (0.30–4.35) |
Form of combination | ||
SEQUENTIAL FORMULATIONS | ||
Ever | 46/191 | 0.80 (0.51–1.20) |
1–4 years | 5/49 | 0.47 (0.17–1.31) |
5–9 years | 14/66 | 0.66 (0.32–1.35) |
10+ years | 22/50 | 1.45 (0.70–3.04) |
CONTINUOUS-COMBINED | ||
Ever | 40/176 | 0.80 (0.50–1.29) |
1–4 years | 8/53 | 0.66 (0.26–1.66) |
5–9 years | 12/52 | 0.56 (0.25–1.20) |
10+ years | 9/47 | 0.65 (0.26–1.67) |
ANY COMBINATION | ||
Ever | 78/324 | 0.85 (0.59–1.21) |
1–4 years | 13/94 | 0.56 (0.28–1.12) |
5–9 years | 23/104 | 0.71 (0.40–1.24) |
10+ years | 28/83 | 1.21 (0.67–2.21) |
CEE/MPA combinations | ||
CEE + MPA | ||
Ever | 3/27 | n.d |
1–4 years | 0/9 | n.d. |
5–9 years | 1/7 | n.d. |
10+ years | 1/10 | n.d. |
CEE or MPA | ||
Ever | 42/142 | 0.64 (0.38–1.10) |
1–4 years | 6/36 | 0.44 (0.16–1.20) |
5–9 years | 13/46 | 0.63 (0.26–1.52) |
10+ years | 20/45 | 1.10 (0.49–2.47) |
No CEE, no MPA | ||
Ever | 80/306 | 0.95 (0.66–1.37) |
1–4 years | 19/89 | 0.87 (0.48–1.59) |
5–9 years | 21/104 | 0.78 (0.44–1.38) |
10+ years | 21/73 | 1.11 (0.58–2.13) |
Formulation content | ||
ONLY – HRTS | ||
ESTROGEN ONLY | ||
Ever | 55/189 | 0.81 (0.51–1.28) |
1–4 years | 8/46 | 0.50 (0.20–1.24) |
5–9 years | 14/66 | 0.98 (0.47–2.06) |
10+ years | 25/60 | 1.07 (0.52–2.19) |
PROGESTAGEN ONLY | ||
Ever | 9/35 | 0.48 (0.17–1.37) |
1–4 years | 1/10 | n.d. |
5–9 years | 2/9 | n.d. |
10+ years | 6/12 | 0.57 (0.13–2.48) |
Estrogen type | ||
ESTRADIOL (E2) | ||
Ever | 80/350 | 0.86 (0.60–1.22) |
1–4 years | 16/99 | 0.73 (0.39–1.36) |
5–9 years | 22/112 | 0.89 (0.52–1.54) |
10+ years | 28/92 | 1.10 (0.62–1.91) |
CONJUGATED EQUINE ESTROGENS (CEE) | ||
Ever | 40/141 | 0.70 (0.41–1.19) |
1–4 years | 5/35 | 0.44 (0.16–1.25) |
5–9 years | 12/47 | 0.61 (0.25–1.49) |
10+ years | 19/49 | 1.30 (0.57–2.73) |
Progestin type | ||
NORETISTERONE ACETATE (NETA) | ||
Ever | 42/193 | 0.78 (0.48–1.25) |
1–4 years | 7/57 | 0.54 (0.20–1.44) |
5–9 years | 13/61 | 0.73 (0.35–1.53) |
10+ years | 14/49 | 0.90 (0.42–1.94) |
LNG | ||
Ever | 22/83 | 0.88 (0.46–1.68) |
1–4 years | 2/21 | 0.45 (0.10–2.08) |
5–9 years | 6/35 | 0.53 (0.19–1.49) |
10+ years | 9/19 | 1.64 (0.51–5.30) |
MEDROXYPROGESTERONE ACETATE (MPA) | ||
Ever | 8/55 | 0.42 (0.16–1.10) |
1–4 years | 1/19 | n.d. |
5–9 years | 3/13 | n.d. |
10+ years | 3/16 | n.d. |
MEDROGESTONE | ||
Ever | 18/65 | 0.87 (0.43–1.73) |
1–4 years | 3/17 | n.d. |
5–9 years | 4/23 | n.d. |
10+ years | 10/19 | 1.81 (0.62–5.28) |
TIBOLONE | ||
Ever | 5/14 | 0.91 (0.26–3.23) |
1–4 years | 2/6 | n.d. |
5–9 years | 0/3 | n.d. |
10+ years | 3/4 | n.d. |